Presentation to Shareholders at AGM 2014
Sydney, Oct 28, 2014 AEST (ABN Newswire) - Regeneus Ltd (
ASX:RGS) Presentation to Shareholders at AGM 2014 with significant achievements to date including the successful translation of 4 regenerative medicine technology platforms into products for musculoskeletal and oncology applications for humans and animals.
Significant Achievements for Regeneus to date:
Successful translation of 4 regenerative medicine technology platforms into products for musculoskeletal and oncology applications for humans and animals
Pioneered autologous ('08) and allogeneic ('11) adipose stem cell therapy for animals in Australia
World's first placebo controlled RCT for autologous adipose stem cell therapy for human knee OA
Largest registry following patients treated with adipose stem cells for human musculoskeletal conditions
USDA green light for first autologous canine cancer vaccine (Kvax)
On track for CryoShot Canine to be one of the first stem cell products approved by FDA
To view the investor presentation, please visit:
http://media.abnnewswire.net/media/en/docs/ASX-RGS-825534.pdf
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
| ||
|
